Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19558821 | 0.82 | NCF1 (0.50) | NCF1HTTCXCR4 | |
| SCHEMBL856292 | 0.79 | NCF1 (0.56) | NCF1HTTPLGPLATLMNA | |
| SCHEMBL19226800 | 0.78 | NCF1 (0.47) | NCF1HTTCXCR4 | |
| Hydrochloric Acid SCHEMBL17796060 | 0.78 | GNAI3 (0.36) | CYP1A2 | |
| SCHEMBL5228967 | 0.77 | PHGDH (0.39) | HTTCYP1A2CHRM3 | |
| SCHEMBL22520384 | 0.76 | NCF1 (0.44) | NCF1HTTCXCR4 | |
| SCHEMBL1972286 | 0.74 | NCF1 (0.47) | NCF1HTTPLGPLATLMNA | |
| SCHEMBL16827090 | 0.73 | NCF1 (0.45) | NCF1HTTPLGPLATLMNA | |
| SCHEMBL22520380 | 0.72 | NCF1 (0.48) | NCF1HTTCHRM2CHRM1CHRM3 | |
| SCHEMBL730979 | 0.71 | NCF1 (0.46) | NCF1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951867-B2 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1543004-A1 | N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER INC. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2004-07-01 | — | — | US | disclosed |
| WO-2004026868-A1 | N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | NCF1 2405/4885HTT 2475/4885CYP1A2 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.